Please login to bookmarkClose

Pharmaceuticals giant Lundbeck has succeeded in overturning IP Australia’s decision granting Novartis unit Sandoz a licence to sell a generic version of top-selling antidepressant Lexapro.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au